Natural Capsules Limited is now listed on both BSE and NSE, with a current market capitalization of approximately ₹261 crore. The NSE listing aligns with NCL’s strategic vision to access a larger pool of investors, increase liquidity, and improve corporate governance standards. Additionally, (NCL) has achieved a significant industry milestone by becoming the second-largest Hard Gelatine Capsules manufacturer in India. This achievement underscores the company’s operational excellence and commitment to innovation.
The NSE listing will enable NCL to enhance transparency, boost corporate governance, and improve credibility. These factors contribute to strengthening investor confidence and reinforcing the company’s reputation in the capital markets.
The NSE listing offers NCL multiple benefits, including increased liquidity through greater trading volumes and improved investor access. It allows broader engagement from institutional and retail investors while strengthening transparency and credibility through enhanced corporate governance. Additionally, it provides comprehensive market coverage across equity, fixed income, and derivative securities, making NCL more visible and attractive to potential investors.
Mr. Sunil Mundra, Managing Director of NCL, stated: “This is a major milestone in NCL’s 32-year journey. The NSE listing will significantly boost our growth trajectory, allowing us to reach a much wider investor base and raise higher volumes of risk capital to undertake larger projects.”
Mr. Raj Kishore Prasad, Chief Financial Officer (CFO) of NCL, commented: “Our NSE listing is a transformational step that enhances liquidity and opens up new avenues for capital raising. It strengthens our commitment to transparency, governance, and market expansion, ultimately benefiting all stakeholders.”
While NCL continues to evaluate new business growth opportunities, acquisitions, and strategic investments, no concrete decisions have been made at this stage. However, the NSE listing plays a crucial role in supporting the company’s long-term growth plans.
With this listing, NCL is poised for a promising future, reinforcing its leadership position in the pharmaceutical and biotech industry while delivering sustained value to its investors.
